Genscript Biotech Corporation (HKG:1548)
13.61
-0.24 (-1.73%)
Apr 27, 2026, 4:08 PM HKT
Genscript Biotech Revenue
In the year 2025, Genscript Biotech had annual revenue of $959.53M USD with 61.40% growth. Genscript Biotech had revenue of $440.75M in the half year ending December 31, 2025.
Revenue
$959.53M
Revenue Growth
+61.40%
P/S Ratio
4.06
Revenue / Employee
$155.64K
Employees
6,165
Market Cap
30.30B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 959.53M | 365.04M | 61.40% |
| Dec 31, 2024 | 594.49M | 34.01M | 6.07% |
| Dec 31, 2023 | 560.48M | -65.22M | -10.42% |
| Dec 31, 2022 | 625.70M | 135.60M | 27.67% |
| Dec 31, 2021 | 490.10M | 99.25M | 25.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Henlius Biotech | 7.42B |
| Zai Lab | 3.58B |
| InnoCare Pharma | 2.87B |
| Shanghai Junshi Biosciences | 2.78B |
| Duality Biotherapeutics | 2.06B |
| Biocytogen Pharmaceuticals (Beijing) | 1.53B |
| Keymed Biosciences | 797.12M |
| Ascentage Pharma Group International | 638.89M |
Genscript Biotech News
- 6 weeks ago - GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth - PRNewsWire
- 6 weeks ago - Genscript Biotech Earnings Call Transcript: H2 2025 - Transcripts
- 9 months ago - Genscript Biotech Earnings Call Transcript: H1 2025 - Transcripts
- 9 months ago - GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation - PRNewsWire
- 9 months ago - GenScript Biotech's MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader - PRNewsWire
- 1 year ago - GenScript Biotech Corporation Reports FY 2024 Results - PRNewsWire
- 1 year ago - Genscript Biotech Earnings Call Transcript: H2 2024 - Transcripts
- 1 year ago - The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development - PRNewsWire